-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 10, the Tianjin Pharmaceutical Procurement Center announced that Merck's new crown oral drug monogravir capsules have been listed on the Tianjin Pharmaceutical Procurement Center, with the first price of 1500 yuan / bottle
.
It is shown that the initial price of monolavir capsules per bottle (40 capsules) is 1500 yuan, and the import CIF price (excluding tax) is between 1100 yuan and 1200
Yuan, while in major countries such as the United States, Japan, South Korea it is $
712.
Initially, the price of monoravir capsules per bottle is lower than the price of Pfizer's new crown oral drug Paxlovid, which pays 1890 yuan per box
for temporary medical insurance in some parts of China.
Merck Monoravir capsules are similar to Pfizer Paxlovid approved indications, both for adult patients with new crown patients with high risk factors for progression to severe disease, specific monolavir capsules are used to treat adult patients with mild to moderate novel coronavirus infection (COVID-19) with risk factors for progression to severe disease, such as patients with advanced age, obesity or overweight, chronic kidney disease, diabetes, severe cardiovascular disease, chronic obstructive pulmonary disease, active cancer and other risk factors for severe disease
。
However, Merck Monolavir capsules are different from the targets chosen to be developed by Pfizer Paxlovid, the former is an RNA polymerase (RdRp) inhibitor, which inhibits or clears the virus by blocking the synthesis of RNA-dependent RNA polymerase of the new coronavirus; The latter belongs to the 3CL protease inhibitor, which disrupts the replication process
of viral RNA by blocking the activity of the new coronavirus 3CL protease.
The data showed that taking Paxlovid within 3 or 5 days after the onset of symptoms can reduce the risk of new crown-related hospitalization or death by up to 89% and 88%, and monoravir can reduce the risk of hospitalization/death by 30%~50%, and can reduce the risk
of death by 89%~100%.
Although Paxlovid did not make it to the 2022 National Health Insurance Catalog, Pfizer CEO Albert
Bourla said at the JP Morgan Healthcare Conference on January 9 that it "is working with partners in China to provide Paxlovid in China starting in the first half of 2023.
"
In August 2022, Pfizer and Huahai Pharmaceutical signed a localized production agreement for Paxlovid, and Huahai Pharmaceutical will provide preparation contract manufacturing services
for Pfizer's new coronavirus treatment Paxlovid sold in the Chinese mainland market during the agreement period (5 years).
According to the agreement, Pfizer will provide nematevir API and ritonavir preparation, and Huahai Pharmaceutical will be responsible for the production of nematevir preparation and complete the combination packaging
.
Pfizer has said that relying on the resource advantages of both parties, the localized production of Paxlovid by Huahai Pharmaceutical will help improve the accessibility of
drugs to patients.
According to Pfizer's financial report, in the second quarter of 2022, Paxlovid achieved global sales of $8.
1 billion; In the third quarter of 2022, Paxlovid generated $7.
514 billion in global sales
.
Resources:
Resources:Oriental wealth
Oriental wealthPublic Information
Public Information
